Monique B Nilsson
Overview
Explore the profile of Monique B Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robichaux J, Elamin Y, Tan Z, Carter B, Zhang S, Liu S, et al.
Nat Med
. 2024 Aug;
30(9):2694-2695.
PMID: 39164519
No abstract available.
2.
Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, et al.
Res Sq
. 2024 Jun;
PMID: 38826463
Traditional feature dimension reduction methods have been widely used to uncover biological patterns or structures within individual spatial transcriptomics data. However, these methods are designed to yield feature representations that...
3.
Heeke S, Gay C, Estecio M, Tran H, Morris B, Zhang B, et al.
Cancer Cell
. 2024 Jan;
42(2):225-237.e5.
PMID: 38278149
Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained challenging, particularly due to limited tissue availability. Given...
4.
Udagawa H, Nilsson M, Robichaux J, He J, Poteete A, Jiang H, et al.
J Thorac Oncol
. 2023 Sep;
19(1):106-118.
PMID: 37678511
Introduction: NRG1 gene fusions are clinically actionable alterations identified in NSCLC and other tumors. Previous studies have reported that NRG1 fusions signal through HER2 and HER3 but, thus far, strategies...
5.
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson M, Yang Y, Heeke S, Patel S, Poteete A, Udagawa H, et al.
Cancer Cell
. 2023 Feb;
41(2):340-355.e6.
PMID: 36787696
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) mediated by...
6.
Patel S, Nilsson M, Yang Y, Le X, Tran H, Elamin Y, et al.
Clin Cancer Res
. 2023 Jan;
29(7):1292-1304.
PMID: 36595561
Purpose: Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR...
7.
Patel S, Nilsson M, Le X, Cascone T, Jain R, Heymach J
Clin Cancer Res
. 2022 Aug;
29(1):30-39.
PMID: 35969170
Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation, growth, and...
8.
Elamin Y, Robichaux J, Carter B, Altan M, Tran H, Gibbons D, et al.
Cancer Cell
. 2022 Jul;
40(7):754-767.e6.
PMID: 35820397
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The study...
9.
Robichaux J, Le X, Vijayan R, Hicks J, Heeke S, Elamin Y, et al.
Nature
. 2021 Sep;
597(7878):732-737.
PMID: 34526717
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver mutations in non-small cell lung cancer (NSCLC). Targeted therapies are approved for patients with 'classical'...
10.
Le X, Nilsson M, Robichaux J, Heymach J
Cancer Cell
. 2021 Aug;
39(9):1178-1180.
PMID: 34388379
The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months,...